TWIST1 and hepatocellular carcinoma: Moreover, Aktas, B et al. detected EMT markers and stem cell markers in 62% and 69% of the CTC-positive patients with metastatic breast cancer, respectively [103], and Li, YM et al. showed that the 80.4% and 84.8% of CTC isolated from patients with hepatocellular carcinoma express vimentin and Twist, respectively [118].